Klebsiella pneumoniae Drug Development Pipeline Study, H2 2018

August 2018 | 90 pages | ID: KF79BFA1AE2EN
VPAResearch

Abstracts

Klebsiella pneumoniae Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Klebsiella pneumoniae pipeline products.

DISEASE OVERVIEW

Klebsiella pneumoniae belongs to the class of Gram-negative bacteria, primarily spread from person-to-person contact or environment but not through air. In normal conditions, Klebsiella Pneumoniae lives in intestines and is not dangerous in healthy individuals. However, based on the route of entry of the bacteria, different infections such as pneumonia, blood/ wound-infections, meningitis etc. occur.

As some of the bacteria are highly resistant to antibiotics, infections caused by the bacteria are difficult for treatment. Accordingly, 25+ companies are investing their resources in development of Klebsiella pneumonia infection treatment pipeline compounds.

Companies currently investing in Klebsiella Pneumoniae pipeline development include%li%ABAC Therapeutics SA, Abgentis Limited, AmpliPhi Biosciences Corporation, Appili Therapeutics Inc, Arsanis Inc, C3J Therapeutics Inc, ContraFect Corporation, Debiopharm International SA, EnBiotix Inc, Evaxion Biotech ApS, Fedora Pharmaceuticals Inc, Forge Therapeutics Inc, Innovation Pharmaceuticals Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Nosopharm SAS, Oryn Therapeutics LLC, Phico Therapeutics Ltd, Shionogi & Co Ltd, Spero Therapeutics Inc, Syntiron LLC, Tetraphase Pharmaceuticals Inc, Vaxdyn SL and Vaxxilon AG.

REPORT DESCRIPTION

The Klebsiella pneumoniae pipeline guide presents complete overview of drugs currently being developed for Klebsiella pneumoniae. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Klebsiella pneumoniae pipeline candidate.

Research and Development progress along with latest news related to each of the Klebsiella pneumoniae pipeline candidates is included.

Major companies participating in therapeutic development of Klebsiella pneumoniae are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Klebsiella pneumoniae from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Klebsiella pneumoniae clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Klebsiella pneumoniae pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF KLEBSIELLA PNEUMONIAE PIPELINE REPORT INCLUDES

• Panorama of Klebsiella pneumoniae pipeline markets including statistics on therapeutic drugs and companies involved
• Klebsiella pneumoniae Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Klebsiella pneumoniae pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Klebsiella pneumoniae pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Klebsiella pneumoniae pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Klebsiella pneumoniae pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Klebsiella pneumoniae pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Klebsiella pneumoniae Pipeline include-
  Number of Companies with Klebsiella pneumoniae projects in pre-clinical Development-
  Number of Companies with Klebsiella pneumoniae projects in Clinical Development-
  Klebsiella pneumoniae Pipeline Companies based in Americas
  Klebsiella pneumoniae Pipeline Companies based in Europe
  Klebsiella pneumoniae Pipeline Companies based in Asia Pacific
  Klebsiella pneumoniae Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
  Klebsiella pneumoniae Pipeline Agents in pre- clinical/Discovery stage of Development
  Klebsiella pneumoniae Pipeline Agents in Clinical Development stage
  Klebsiella pneumoniae Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs-
  Small molecules among the Klebsiella pneumoniae Pipeline agents

II. INSIGHTS INTO KLEBSIELLA PNEUMONIAE PIPELINE

1. Disease Overview
  Introduction to Klebsiella pneumoniae
  Symptoms and Causes of Klebsiella pneumoniae
  Treatment or Prevention Options for Klebsiella pneumoniae
  Other Details
2. Phase wise Pipeline Compounds
  Klebsiella pneumoniae Pipeline- Pre- Clinical/Discovery stage Drugs
  Klebsiella pneumoniae Pipeline- Phase 1 stage Drugs
  Klebsiella pneumoniae Pipeline- Phase 2 stage Drugs
  Klebsiella pneumoniae Pipeline- Phase 3 stage Drugs
  Klebsiella pneumoniae Pipeline- Pre-Registration stage Drugs
3. Company wise Klebsiella pneumoniae Pipeline Compounds
4. Klebsiella pneumoniae Pipeline by Mechanism of Action

III. KLEBSIELLA PNEUMONIAE PIPELINE COMPOUND DETAILS

Small Molecules for K.pneumoniae Infections
GYR12
BioPhage therapeutics
ATI-1503
ASN300
C3J-EP-XX
Gram Negative Bacterial Infections
Debio 1454
EBX-004
EVX-B4 VAP
FPI-1465
Small Molecules for Bacterial Infections
Lpxc
CTIX1278
LCB18-0055
RX-04
RX-P873
NOSO-502
OTP-602
PT4
cefiderocol
SPR741
Klebsiella pneumoniae vaccine(Syntiron)
TP-6076
bacterial infection therapeutics
Klebsiella pneumoniae vaccine
VRP-001
Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co-Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. KLEBSIELLA PNEUMONIAE PIPELINE COMPANY BRIEFS

ABAC Therapeutics SA
Abgentis Ltd
AmpliPhi Biosciences Corp
Appili Therapeutics Inc
Arsanis Inc
C3J Therapeutics Inc
ContraFect Corporation
Debiopharm International SA
EnBiotix Inc
Evaxion Biotech ApS
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
Innovation Pharmaceuticals Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Nosopharm SAS
Oryn Therapeutics LLC
Phico Therapeutics Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Vaxdyn SL
Vaxxilon AG

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL KLEBSIELLA PNEUMONIAE PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability